Literature DB >> 32295854

Functional Index-3: A Valid and Reliable Functional Outcome Assessment Measure in Patients With Dermatomyositis and Polymyositis.

Floranne C Ernste1, Christopher Chong2, Cynthia S Crowson3, Tanaz A Kermani4, Orla Ni Mhuircheartaigh5, Helene Alexanderson6.   

Abstract

OBJECTIVE: Patients with dermatomyositis (DM) and polymyositis (PM) have reduced muscle endurance.The aim of this study was to streamline the Functional Index-2 (FI-2) by developing the Functional Index-3 (FI-3) and to evaluate its measurement properties, content and construct validity, and intra- and interrater reliability.
METHODS: A dataset of the previously performed and validated FI-2 (n = 63) was analyzed for internal redundancy, floor, and ceiling effects. The content of the FI-2 was revised into the FI-3. Construct validity and intrarater reliability of FI-3 were tested on 43 DM and PM patients at 2 rheumatology centers. Interrater reliability was tested in 25 patients. The construct validity was compared with the Myositis Activities Profile (MAP), Health Assessment Questionnaire (HAQ), and Borg CR-10 using Spearman correlation coefficient.
RESULTS: Spearman correlation coefficients of 63 patients performing FI-3 revealed moderate to high correlations between shoulder flexion and hip flexion tasks and similar correlations with MAP and HAQ scores; there were lower correlations for neck flexion task. All FI-3 tasks had very low to moderate correlations with the Borg scale. Intraclass correlation coefficients (ICC) of FI-3 tasks for intrarater reliability (n = 25) were moderate to good (0.88-0.98). ICC of FI-3 tasks for interrater reliability (n = 17) were fair to good (range 0.83-0.96).
CONCLUSION: The FI-3 is an efficient and valid method for clinically assessing muscle endurance in DM and PM patients. FI-3 construct validity is supported by the significant correlations between functional tasks and the MAP, HAQ, and Borg CR-10 scores.

Entities:  

Keywords:  Functional Index-2; idiopathic inflammatory myopathies; muscle endurance; outcome measures

Mesh:

Year:  2020        PMID: 32295854      PMCID: PMC7572829          DOI: 10.3899/jrheum.191374

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  22 in total

1.  Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls.

Authors:  G F Wiesinger; M Quittan; M Nuhr; B Volc-Platzer; G Ebenbichler; M Zehetgruber; W Graninger
Journal:  Arch Phys Med Rehabil       Date:  2000-01       Impact factor: 3.966

Review 2.  Defining Clinical Improvement in Adult and Juvenile Myositis.

Authors:  Lisa G Rider; Edward H Giannini; Michael Harris-Love; Galen Joe; David Isenberg; Clarissa Pilkington; Peter A Lachenbruch; Frederick W Miller
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

3.  Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

Authors:  M O Harris-Love; J A Shrader; D Koziol; N Pahlajani; M Jain; M Smith; H L Cintas; C L McGarvey; L James-Newton; A Pokrovnichka; B Moini; I Cabalar; D J Lovell; R Wesley; P H Plotz; F W Miller; J E Hicks; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2008-12-11       Impact factor: 7.580

4.  Psychophysical bases of perceived exertion.

Authors:  G A Borg
Journal:  Med Sci Sports Exerc       Date:  1982       Impact factor: 5.411

5.  Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies - evident in chronic but not in untreated newly diagnosed patients.

Authors:  I Loell; S B Helmers; M Dastmalchi; H Alexanderson; L A Munters; I Nennesmo; E Lindroos; K Borg; I E Lundberg; M Esbjörnsson
Journal:  Clin Physiol Funct Imaging       Date:  2010-10-01       Impact factor: 2.273

6.  Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis.

Authors:  Helene Alexanderson; Maryam Dastmalchi; Mona Esbjörnsson-Liljedahl; Christina H Opava; Ingrid E Lundberg
Journal:  Arthritis Rheum       Date:  2007-06-15

7.  Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis.

Authors:  Helene Alexanderson; Lisbet Broman; Anna Tollbäck; Annika Josefson; Ingrid E Lundberg; Christina H Stenström
Journal:  Arthritis Rheum       Date:  2006-02-15

8.  Reliability of the adult myopathy assessment tool in individuals with myositis.

Authors:  Michael O Harris-Love; Galen Joe; Todd E Davenport; Deloris Koziol; Kristen Abbett Rose; Joseph A Shrader; Olavo M Vasconcelos; Beverly McElroy; Marinos C Dalakas
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-04       Impact factor: 4.794

9.  Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study.

Authors:  Helene Alexanderson; Malin Regardt; Christina Ottosson; Li Alemo Munters; Maryam Dastmalchi; Lara Dani; Ingrid E Lundberg
Journal:  J Rheumatol       Date:  2018-02-01       Impact factor: 4.666

10.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02
View more
  3 in total

Review 1.  Assessment of Physical Activity and Muscle Function in Adult Inflammatory Myopathies.

Authors:  William J Gregory; Didem Saygin
Journal:  Curr Rheumatol Rep       Date:  2022-03-04       Impact factor: 4.592

Review 2.  Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS).

Authors:  Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-07-01       Impact factor: 4.991

3.  Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods - a qualitative study.

Authors:  Alexander Oldroyd; William Dixon; Hector Chinoy; Kelly Howells
Journal:  BMC Rheumatol       Date:  2020-09-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.